It offers better efficacy than orally administered carbidopa-levodopa, dosing flexibility and a more convenient pump than existing and upcoming competitors; 6) Lecanemab: Clarivate delivers a vote ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Clarivate Plc, a leading global provider of transformative ... rather than traditional dopamine pathways, while minimizing cholinergic side effects. While further data is needed to assess its ...

In this article, we are going to take a look at where Clarivate Plc (NYSE:CLVT) stands against other non-tech AI opportunities amid DeepSeek selloff. Investors are searching for safer ways to ...

LONDON, Jan. 30, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released The top 50 universities powering global innovation report ...

“The rise of China in publication output and world share in internationally influential journals indexed in the Web of Science has been a dramatic development during the last 20 years,” David ...

Clarivate’s Drugs to Watch in 2025 report (PDF) predicts that Novo’s new once-weekly insulin Awiqli will pick up $4.7 billion in sales by 2030, making it one of the hottest launches of the year.

LONDON, Jan. 8, 2025 /CNW/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report ...

At Clarivate, we take pride in the precision ... rather than traditional dopamine pathways, while minimizing cholinergic side effects. While further data is needed to assess its effectiveness ...